It's a somber reminder that it is hard to crack the goal - as seen by MSB.
But in light of this, once again reminds me that IHL is very well positioned in the market as ARDS is not the only thing that we have on our pipeline, unlike MSB.
So any positive progress on IHL675A will continue to add value to the company and even if the result goes the other way, it won't destroy the SP in half.
Ann: Positive IHL-675A in vivo results and FDA Pathway, page-122
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)